TY - JOUR
T1 - Psychopharmacology in children and adolescents
T2 - unmet needs and opportunities
AU - Cortese, Samuele
AU - Purper-Ouakil, Diane
AU - Apter, Alan
AU - Arango, Celso
AU - Baeza, Inmaculada
AU - Banaschewski, Tobias
AU - Buitelaar, Jan
AU - Castro-Fornieles, Josefina
AU - Coghill, David
AU - Cohen, David
AU - Correll, Christoph U.
AU - Grünblatt, Edna
AU - Hoekstra, Pieter J.
AU - James, Anthony
AU - Jeppesen, Pia
AU - Nagy, Péter
AU - Pagsberg, Anne Katrine
AU - Parellada, Mara
AU - Persico, Antonio M.
AU - Roessner, Veit
AU - Santosh, Paramala
AU - Simonoff, Emily
AU - Stevanovic, Dejan
AU - Stringaris, Argyris
AU - Vitiello, Benedetto
AU - Walitza, Susanne
AU - Weizman, Abraham
AU - Wong, Ian C.K.
AU - Zalsman, Gil
AU - Zuddas, Alessandro
AU - Carucci, Sara
AU - Butlen-Ducuing, Florence
AU - Tome, Maria
AU - Bea, Myriam
AU - Getin, Christine
AU - Hovén, Nina
AU - Konradsson-Geuken, Asa
AU - Lamirell, Daphne
AU - Olisa, Nigel
AU - Nafria Escalera, Begonya
AU - Moreno, Carmen
PY - 2024/2
Y1 - 2024/2
N2 - Psychopharmacological treatment is an important component of the multimodal intervention approach to treating mental health conditions in children and adolescents. Currently, there are many unmet needs but also opportunities, alongside possible risks to consider, regarding the pharmacological treatment of mental health conditions in children and adolescents. In this Position Paper, we highlight and address these unmet needs and opportunities, including the perspectives of clinicians and researchers from the European College of Neuropsychopharmacology–Child and Adolescent Network, alongside those of experts by lived experience from national and international associations, via a survey involving 644 participants from 13 countries, and of regulators, through representation from the European Medicines Agency. We present and discuss the evidence base for medications currently used for mental disorders in children and adolescents, medications in the pipeline, opportunities in the development of novel medications, crucial priorities for the conduct of future clinical studies, challenges and opportunities in terms of the regulatory and legislative framework, and innovations in the way research is conducted, reported, and promoted.
AB - Psychopharmacological treatment is an important component of the multimodal intervention approach to treating mental health conditions in children and adolescents. Currently, there are many unmet needs but also opportunities, alongside possible risks to consider, regarding the pharmacological treatment of mental health conditions in children and adolescents. In this Position Paper, we highlight and address these unmet needs and opportunities, including the perspectives of clinicians and researchers from the European College of Neuropsychopharmacology–Child and Adolescent Network, alongside those of experts by lived experience from national and international associations, via a survey involving 644 participants from 13 countries, and of regulators, through representation from the European Medicines Agency. We present and discuss the evidence base for medications currently used for mental disorders in children and adolescents, medications in the pipeline, opportunities in the development of novel medications, crucial priorities for the conduct of future clinical studies, challenges and opportunities in terms of the regulatory and legislative framework, and innovations in the way research is conducted, reported, and promoted.
KW - Adolescent
KW - Humans
KW - Mental Disorders/drug therapy
KW - Mental Health
KW - Psychopharmacology
UR - https://www.sciencedirect.com/science/article/abs/pii/S2215036623003450
UR - https://www.scopus.com/pages/publications/85181653674
U2 - 10.1016/S2215-0366(23)00345-0
DO - 10.1016/S2215-0366(23)00345-0
M3 - Review article
C2 - 38071998
AN - SCOPUS:85181653674
SN - 2215-0366
VL - 11
SP - 143
EP - 154
JO - The Lancet Psychiatry
JF - The Lancet Psychiatry
IS - 2
ER -
SDG 3 Good Health and Well-being